MGMT and central nervous system cancer: On the other hand, Oldrini and colleagues (2021) reported that MGMT genomic rearrangements carried by a subset of recurrent gliomas led to MGMT overexpression and TMZ resistance in vitro and in vivo, independently from changes in its promoter methylation [200].